Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBIT Margin: 2021-2025

Historic EBIT Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -102.64%.

  • Rhythm Pharmaceuticals' EBIT Margin rose 2934.00% to -102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -106.81%, marking a year-over-year increase of 12914.00%. This contributed to the annual value of -204.04% for FY2024, which is 3407.00% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' EBIT Margin stood at -102.64%, which was down 9.91% from -93.39% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBIT Margin peaked at -93.39% during Q2 2025, and registered a low of -98,280.00% during Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' EBIT Margin had a median value of -143.73% in 2025 and averaged -210.40%.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' EBIT Margin surged by 9,476,258bps in 2022, and later crashed by 8,068bps in 2024.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' EBIT Margin stood at -2,806.22% in 2021, then surged by 232,723bps to -478.99% in 2022, then soared by 30,871bps to -170.28% in 2023, then spiked by 7,165bps to -98.63% in 2024, then surged by 2,934bps to -102.64% in 2025.
  • Its last three reported values are -102.64% in Q3 2025, -93.39% for Q2 2025, and -143.73% during Q1 2025.